Scott A Laurie - JoVE Visualize

Showing results (51-60 of 70) with videos related to

Pageof 7

Sort By:

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2017

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateArlene A Forastiere, Nofisat Ismaila, Jan S Lewin, et al.

Nature Medicine|October 9, 2023

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial resultsValsamo Anagnostou, Cheryl Ho, Garth Nicholas, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 studyGlenwood D Goss, Andrew Arnold, Frances A Shepherd, et al.

The Lancet. Oncology|December 10, 2016

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort studyMatthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.

British Journal of Cancer|February 19, 2016

Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patientsPetra Martin, Carolyn J Shiau, Maria Pasic, et al.

Therapeutic Advances in Medical Oncology|August 4, 2022

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancerDoreen A Ezeife, Eldon Spackman, Rosalyn A Juergens, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 20, 2021

CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLCNatasha B Leighl, Scott A Laurie, Glenwood D Goss, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2006

American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer, David G Pfister, Scott A Laurie, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 10, 2019

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 StudyByoung Chul Cho, Radka Obermannova, Alessandra Bearz, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2016

BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 TrialGeoffrey Liu, Sinead Cuffe, Shermi Liang, et al.

Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:

Pageof 7

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 28, 2017

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateArlene A Forastiere, Nofisat Ismaila, Jan S Lewin, et al.

Nature Medicine|October 9, 2023

ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial resultsValsamo Anagnostou, Cheryl Ho, Garth Nicholas, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 studyGlenwood D Goss, Andrew Arnold, Frances A Shepherd, et al.

The Lancet. Oncology|December 10, 2016

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort studyMatthew D Hellmann, Naiyer A Rizvi, Jonathan W Goldman, et al.

British Journal of Cancer|February 19, 2016

Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patientsPetra Martin, Carolyn J Shiau, Maria Pasic, et al.

Therapeutic Advances in Medical Oncology|August 4, 2022

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancerDoreen A Ezeife, Eldon Spackman, Rosalyn A Juergens, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 20, 2021

CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLCNatasha B Leighl, Scott A Laurie, Glenwood D Goss, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2006

American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer, David G Pfister, Scott A Laurie, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 10, 2019

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 StudyByoung Chul Cho, Radka Obermannova, Alessandra Bearz, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2016

BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 TrialGeoffrey Liu, Sinead Cuffe, Shermi Liang, et al.

Pageof 7